Program:
Sun. 3/10-Registration-KEYNOTE ADDRESS: F. Lejeune , CHUV, "The Mechanism of Anti-Tumor Activity of High Dose Intravascular TNF"
Mon. 3/11-MECHANISMS OF ANTITUMOR EFFECT WITH TNF I: N. Jaskowiak, National Cancer Inst, "Secondary Cytokine Production and Endocrine Effects after High Dose Intravascular TNF"; H. Dvorak, Beth Israel Hosp, "Pathology of Responding Tumors Following Isolation Perfusion with TNF"; Speakers to be Announced-POSTER SESSION 1-MECHANISMS OF ANTITUMOR EFFECT WITH TNF II: M. Schwarz, Columbia Univ, "EMAPII: A Novel Antiangiogenic Cytokine"; R. Jain , Massachusetts General Hosp, "Tumor Interstitial Hydrostatic Pressure: Effects of TNF and Impact on Delivery of Intravascular Agents"; P. Nooijen , Univ Hospital-Nijmegan, "Effect of High Dose TNF Delivered by Regional Perfusion on Vascular Endothelial Cells"
Tues. 3/12-SYNERGISTIC ACTION BETWEEN TNF, CHEMOTHERAPEUTICS, AND HYPERTHERMIA I: I. Robins, Univ Wisconsin Cancer Ctr, "The Use of Systemic TNF in Conjunction with Whole Body Hyperthermia and Chemotherapeutics"; J. Klostergaard, MD Anderson Cancer Ctr, "Preclinical Studies of Modified and Liposomal TNF"; B. Bonavida , Univ California-Los Angeles, "Synergistic Cytotoxic Interactions of TNF with Chemotherapeutics"; Speaker to be Announced-POSTER SESSION 2-SYNERGISTIC ACTION BETWEEN TNF, CHEMOTHERAPEUTICS, AND HYPERTHERMIA II: Speakers to be Announced
Wed. 3/13-DIRECT CYTOTOXICITY WITH TNF AND RECEPTOR SELECTIVE MUTEINS I: W. Fiers, Univ Ghent, "TNF-Receptor Specific TNF Mutants: Mechanism of Action at the Cellular and in vivo Level"; J. Fruehauf, Oncotech, Inc, "A GKD TNF Degradation Products Contributes to TNF Antitumor Activity: Preclinical Development and Characterization"; D. Spriggs , Sloan-Kettering Cancer Center, "Production of TNF as a Mechanism for Proposed Resistence to TNF Cytotoxicity in vitro"-POSTER SESSION 3-DIRECT CYTOTOXICITY WITH TNF AND RECEPTOR SELECTIVE MUTEINS I: C. Ware , Univ California-Riverside, "Characterization and Signaling Through Distinct TNF Receptors"; S. Jacobsen, Hipple Cancer Rsch Ctr, "The Role of TNF and Fas in Hematopoiesis"; Speaker to be Announced
Thur. 3/14-POTENTIAL CLINICAL USE OF RELATED CYTOKINES I: G. Wong, Genentech, Inc, "New Clinical Indications for Lymphotoxin"; D. Vlock , Brigham and Women's Hosp, "Potential Clinical Applications of Recombinant IL-1"; C. Johnson, Univ Pittsburgh Sch Med, "Cytokine Enhancement of Chemotherapeutic Efficacy: Role of the Vasculature"-POSTER SESSION 4-POTENTIAL CLINICAL USE OF RELATED CYTOKINES II: Speakers to be Announced
Fri. 3/15-CLINICAL TRIALS OF REGIONAL TNF I: A. Eggermont, Rotterdam Cancer Inst, "Limb Perfusion with TNF: Current Status of European Trials"; J. Klausner, Tel Aviv Univ, "The Use of TNF in Isolated Limb Perfusion for Treatment of Unresectable Extremity Sarcoma"; D. Fraker, National Cancer Inst, "Isolated Hepatic Perfusion with TNF"; D. Fraker, Univ Pennsylvania, "Limb Perfusion with TNF: Current Status of United States Trials"-CLINICAL TRIALS OF REGIONAL TNF II: H. Pass , National Cancer Inst, "Isolated Lung Perfusion with TNF"; R. Alexander, National Cancer Inst, "The Use of TNF in Continuous Hyperthermic Peritoneal Perfusions"; D. Lienard , CHUV, "The Use of TNF in Isolated Limb Perfusion for Treatment of Locally Advanced Melanoma"-Banquet (Please note: There are NO POSTERS on banquet day.)
Sat. 3/16-Departure
Registration :
Cambridge Symposia
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone: 617-630-1399
Fax: 617-630-1395
e-mail: symposia@xensei.com
http://www.xensei.com/users/symposia
Deadline for Abstracts: December 6, 1996
Email for Requests and Registration: symposia@xensei.com